DPRP Inhibitors
DPRP inhibitors are a class of chemical compounds specifically designed to inhibit the function of DPRP, which stands for dual-specificity phosphatase-related protein, possibly part of the family of phosphatases involved in regulating phosphorylation events in cells. Phosphatases like DPRP play a critical role in cellular signaling by dephosphorylating serine, threonine, or tyrosine residues on proteins. These phosphorylation and dephosphorylation events act as molecular switches that regulate various cellular functions, such as signal transduction, cell growth, and metabolism. By inhibiting DPRP, researchers can investigate how it modulates these phosphorylation-dependent processes, offering insights into how phosphatases contribute to cellular homeostasis and the balance of kinase-phosphatase activity.
The mechanism of action for DPRP inhibitors generally involves blocking the enzyme's catalytic site, preventing the hydrolysis of phosphate groups from its substrate proteins. These inhibitors may bind to the active site of DPRP, competing with the phosphorylated substrate, or they might interact with allosteric sites, causing conformational changes that inactivate the enzyme. Structurally, DPRP inhibitors are often designed to mimic the phosphorylated state of the target protein, allowing them to bind with high specificity to the phosphatase. Through the use of DPRP inhibitors, researchers can explore how the regulation of phosphorylation states affects intracellular signaling pathways and protein interactions. These inhibitors are essential tools for dissecting the dynamic regulation of cellular processes such as cell division, stress responses, and metabolic pathways, providing a deeper understanding of the role phosphatases like DPRP play in coordinating cellular signaling networks.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
A folic acid analog inhibiting dihydrofolate reductase, disrupting folate metabolism. This disrupts nucleotide synthesis, indirectly influencing Prl8a2 by affecting cellular processes dependent on nucleotide availability. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3-kinase inhibitor disrupting the PI3K/Akt signaling pathway. This indirectly inhibits Prl8a2 by interfering with downstream signaling events crucial for its activation and subsequent hormonal activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor affecting the mTOR signaling pathway. Its action indirectly inhibits Prl8a2 by interfering with cellular processes regulated by mTOR that contribute to the hormone activity and receptor binding of Prl8a2. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAPK inhibitor disrupting the p38 MAPK signaling pathway. This indirectly inhibits Prl8a2 by modulating downstream events within the pathway that influence the hormonal activity and receptor binding of Prl8a2. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor targeting the JNK signaling pathway. It indirectly inhibits Prl8a2 by disrupting the JNK pathway, influencing cellular processes related to hormone activity and prolactin receptor binding associated with Prl8a2. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3-kinase inhibitor affecting the PI3K/Akt pathway. This indirectly inhibits Prl8a2 by interfering with the signaling cascade that contributes to its hormonal activity and prolactin receptor binding. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor disrupting protein degradation. It indirectly inhibits Prl8a2 by impacting the degradation of proteins involved in the regulation of hormonal activity and prolactin receptor binding associated with Prl8a2. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Multi-kinase inhibitor influencing Raf/MEK/ERK signaling. It indirectly inhibits Prl8a2 by disrupting the Raf/MEK/ERK pathway, which plays a role in the hormonal activity and receptor binding associated with Prl8a2. | ||||||
Tozasertib | 639089-54-6 | sc-358750 sc-358750A | 25 mg 50 mg | $61.00 $85.00 | 4 | |
Aurora kinase inhibitor affecting cell cycle progression. It indirectly inhibits Prl8a2 by modulating cell cycle events that contribute to the hormonal activity and prolactin receptor binding associated with Prl8a2. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor targeting the MAPK pathway. This indirectly inhibits Prl8a2 by disrupting the MAPK pathway, which is involved in the regulation of hormonal activity and prolactin receptor binding associated with Prl8a2. | ||||||